Oppenheimer reiterates Harmony Biosciences Holdings (HRMY) outperformance recommendation
Fintel reports that on May 26, 2023, Oppenheimer reiterated cover of Harmony Biosciences Holdings (NASDAQ: HRMY) with a Surpass recommendation.
Analyst price predictions suggest a 71.94% rise
As of May 11, 2023, the average duration of one year target price for Harmony Biosciences Holdings is 61.88. The forecast ranges from a low of 38.38 to a high of $78.75. The average price target represents a 71.94% increase from its last published closing price of 35.99.
See our company ranking with the biggest price target on the upside.
The expected annual revenue for Harmony Biosciences Holdings is 591 million, an increase of 25.35%. The projected annual non-GAAP PES is 2.76.
What is fund sentiment?
There is 557 funds or institutions reporting positions in Harmony Biosciences Holdings. This is an increase of 3 owner(s) or 0.54% over the last quarter. Average portfolio weight of all funds dedicated to HRMY is 0.39%, a decrease of 12.97%. The total number of shares held by institutions has decreased by 0.13% over the past three months to 57,151,000 shares. THE put/call ratio of HRMY is 7.42, indicating a bearish outlook.
What are the other shareholders doing?
Valor Management holds 11,218,000 shares representing 18.71% ownership of the company. No change in the last quarter.
Living capital holds 2,606,000 shares representing 4.35% ownership of the company. No change in the last quarter.
IJR – iShares Core S&P Small-Cap ETF holds 2,157,000 shares representing 3.60% ownership of the company. In its previous filing, the company stated that it holds 2,203,000 shares, representing a decrease 2.15%. The company decreases its portfolio allocation in HRMY of 43.64% in the last quarter.
FDGRX – Fidelity Growth Company Fund holds 1,783,000 shares representing 2.97% ownership of the company. In its previous filing, the company said it held 1,827,000 shares, representing a decrease of 2.41%. The company decreases its portfolio allocation in HRMY by 26.15% in the last quarter.
Adage Capital Partners Gp, Llc holds 1,415,000 shares representing 2.36% ownership of the company. In its previous filing, the company said it held 130,000 shares, representing a raise of 90.81%. The company increase its portfolio allocation in HRMY of 504.74% in the last quarter.
General information about Harmony Biosciences Holdings
(This description is provided by the company.)
Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company is focused on the research, drug development and treatment of the neurological disorder of sleep-wake state instability. Harmony Biosciences Holdings serves patients in the United States.
Key deposits for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Oppenheimer reiterates Harmony Biosciences Holdings (HRMY) outperformance recommendation
